Alpha tocopherol protects against immunosuppressive and immunotoxic effects of lead.
Chronic exposure to lead (Pb) is associated with multiorgan toxicity. The precise mechanism(s) involved, however, remains incompletely defined. The present study was undertaken to analyze the effect of Pb on the immune system and determine the ability of alpha tocopherol (AT) to reverse Pb-induced immunotoxicity. Groups of TO Mice (6 per group) were treated ip for 2 weeks with saline alone, Pb acetate alone, Pb plus AT, or with AT alone. Spleens were then analyzed for (i) cellular composition by flow cytometry, (ii) cellular response to B and T cell mitogens and (iii) production of nitric oxide (NO). Pb treatment resulted in a significant state of splenomegaly associated mainly with an influx of CD11b+ myeloid cells. Surprisingly, however, these cells exhibited no upregulation in expression of activation markers and did not produce NO. The lymphocyte mitogenic responses were inhibited by > or = 70% in Pb-treated group. Concurrent treatment with Pb and AT resulted in almost a complete reversal of Pb-induced splenic cellular influx. Despite this, however, mitogenic responses in Pb + AT treated group were approximately 50% of those observed in normal (saline-treated) controls. We conclude that (1) chronic treatment with Pb acetate induces a state of splenomegaly and decreased proliferation in response to mitogenic stimuli and (2) co-treatment with AT largely reversed the cellular influx but this was associated with only a partial improvement of the mitogenic responses. These results highlight the role of AT as a potentially effective antioxidant in the immune system.
Department of Biochemistry, Faculty of Medicine and Health Sciences, UAE University, P.O. Box 17666, Al Ain, United Arab Emirates.
Maria J
MJ
Fernandez-Cabezudo
Mohammed Y
MY
Hasan
Nada
N
Mustafa
Rami T
RT
El-Sharkawy
Mohamed A
MA
Fahim
Basel K
BK
Al-Ramadi
D000818:Animals; D039481:CD11b Antigen / Q000096:biosynthesis; D002455:Cell Division / Q000187:drug effects; D003208:Concanavalin A / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007854:Lead / Q000494:pharmacology / Q000633:toxicity*; D008070:Lipopolysaccharides / Q000378:metabolism; D008297:Male; D051379:Mice; D009569:Nitric Oxide / Q000378:metabolism; D010641:Phenotype; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D013163:Splenomegaly; D015854:Up-Regulation; D024502:alpha-Tocopherol / Q000494:pharmacology*
D039481:CD11b Antigen; D007166:Immunosuppressive Agents; D008070:Lipopolysaccharides; D003208:Concanavalin A; D007854:Lead; D009569:Nitric Oxide; D024502:alpha-Tocopherol